STOCK TITAN
  1. Home
  2. Sec-filings
  3. PTCT
  4. [Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

PTC Therapeutics (NASDAQ: PTCT) SVP sells stock to cover taxes shares

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

PTC Therapeutics senior executive Christine Marie Utter reported automatic stock sales linked to restricted stock unit (RSU) vesting. As SVP and Chief Accounting Officer, she sold 1,381 shares of common stock at $76.95 on January 6, 2026 and 1,235 shares at $77.45 on January 7, 2026.

According to the footnotes, both sales were made under irrevocable “sell to cover” elections entered into when the RSU grants were accepted, solely to satisfy tax withholding obligations on the vesting of 3,500 RSUs from separate 14,000‑share grants. After these transactions, she directly owns 73,727 shares of PTC Therapeutics common stock.

Positive

  • None.

Negative

  • None.
Insider Utter Christine Marie
Role SVP, CHIEF ACCOUNTING OFFICER
Sold 2,616 shs ($202K)
Type Security Shares Price Value
Sale Common Stock 1,235 $77.45 $96K
Sale Common Stock 1,381 $76.95 $106K
Holdings After Transaction: Common Stock — 73,727 shares (Direct)
Footnotes (1)
  1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a January 3, 2025 grant of 14,000 RSUs. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a January 5, 2023 grant of 14,000 RSUs.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Utter Christine Marie
(Last) (First) (Middle)
C/O PTC THERAPEUTICS, INC.
500 WARREN CORPORATE CENTER DRIVE
(Street)
WARREN NJ 07059
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, CHIEF ACCOUNTING OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/06/2026 S 1,381(1) D $76.95 74,962 D
Common Stock 01/07/2026 S 1,235(2) D $77.45 73,727 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a January 3, 2025 grant of 14,000 RSUs.
2. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 3,500 RSUs from a January 5, 2023 grant of 14,000 RSUs.
/s/ Avraham S. Adler, Attorney-in-Fact 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did PTC Therapeutics (PTCT) report in this Form 4?

The Form 4 reports that Christine Marie Utter, SVP and Chief Accounting Officer of PTC Therapeutics, sold 1,381 shares of common stock on January 6, 2026 at $76.95 per share and 1,235 shares on January 7, 2026 at $77.45 per share.

Were the PTC Therapeutics insider sales discretionary or for tax withholding?

The filing states that both transactions represent shares automatically sold under an irrevocable sell to cover election made when the RSU grants were accepted, to satisfy tax withholding obligations upon vesting of RSUs.

How many PTC Therapeutics shares does Christine Marie Utter own after these transactions?

Following the reported transactions, Christine Marie Utter beneficially owns 73,727 shares of PTC Therapeutics common stock directly.

What RSU grants are linked to the reported PTC Therapeutics share sales?

The first sale relates to the vesting of 3,500 RSUs from a January 3, 2025 grant of 14,000 RSUs. The second sale relates to the vesting of 3,500 RSUs from a January 5, 2023 grant of 14,000 RSUs.

What is Christine Marie Utter’s role at PTC Therapeutics?

Christine Marie Utter is identified in the filing as an officer of PTC Therapeutics, serving as SVP, Chief Accounting Officer.

Is this PTC Therapeutics Form 4 filed for one reporting person or a group?

The document shows that the Form 4 is filed by one reporting person, covering transactions by Christine Marie Utter only.